FDA warns Acceleron of possible fines for not posting results from failed trial
In a first for the FDA, the agency on Wednesday said that it sent a notice of noncompliance to Acceleron Pharma for its failure to post results from a cancer trial, and said the company has 30 days to correct this failure or it may have to pay a $10,000 penalty or face criminal prosecution.
The letter opens a big can of worms for biopharma companies, which have a legal responsibility to post trial results to the government’s database at ClinicalTrials.gov, generally no later than one year after the study’s completion date unless a deadline extension is obtained. But many companies, even if they’re transparent about the results, fail to update the listings in the database.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.